share_log

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

aclaris therapeutics將參加派傑投資第36屆年度醫療保健大會
GlobeNewswire ·  11/27 05:30

WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 1:00 PM ET in New York, New York.

賓夕法尼亞州韋恩,2024年11月26日(環球新聞通訊)—— aclaris therapeutics, inc.(納斯達克:ACRS),一家專注於開發用於免疫炎症疾病的新型藥物候選的臨床階段生物製藥公司,今天宣佈,aclaris管理團隊的成員將參加於2024年12月3日下午1:00(東部時間)在紐約市舉行的派傑投資第36屆年度醫療保健會議的爐邊聊天。

A webcast of the fireside chat may be accessed through the "Events" page of the "Investors" section of Aclaris' website, . The webcast will be archived for at least 30 days on the Aclaris website.

通過Aclaris官網的「投資者」版塊的「活動」頁面,可以訪問座談會的網絡直播。該網絡直播將在Aclaris官網存檔至少30天。

About Aclaris Therapeutics, Inc.

關於Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit .

Aclaris Therapeutics, Inc.是一家臨床階段的生物製藥公司,致力於開發一系列新型藥物候選品,以滿足免疫炎症性疾病患者的需求,這些患者缺乏滿意的治療選擇。該公司擁有一個多階段的藥物候選品組合,由強大的研發引擎驅動,探索蛋白激酶調控。更多信息請訪問。

Aclaris Therapeutics Contact:

Aclaris Therapeutics 聯繫方式:

investors@aclaristx.com

investors@aclaristx.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論